PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Latest Episodes:

Taofeek K. Owonikoko, MD, PhD - Progress on the Path to Improving Outcomes in the Treatment of SCLC: Making the Most of Current Standard-of-Care Therapies and Exploring New Promising Research Jun 30, 2023

Show notes

Go online to PeerView.com/WFE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Important advances have occurred in the treatment of small cell lung cancer (SCLC) in recent years, and more exciting progress in the form of improved understanding of the disease biology, subtypes, and novel therapies is on the horizon. This educational activity, based on a recent live symposium produced in collaboration with LUNGevity Foundation, offers useful guidance for navigating the evidence supporting the use of current and emerging therapies in SCLC and translating the latest science to everyday clinical practice. Upon completion of this activity, participants should be better able to: Discuss the rationale, current or emerging clinical roles, and evidence supporting the use of the latest therapies for SCLC; Integrate the current standard-of-care therapies into individualized treatment plans of eligible patients with SCLC based on the latest evidence, guideline recommendations, and patient needs/preferences; and Recommend enrollment in clinical trials evaluating current and new/emerging therapies to eligible patients with SCLC.

Benjamin M. Brucker, MD - Can We Improve Management of Overactive Bladder in Long-Term Care? Examining the Role of Beta-3 Adrenergic Agonists Jun 29, 2023

Show notes

Go online to PeerView.com/QGG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Overactive bladder is frequently underdiagnosed and undertreated, but fortunately there's a newer treatment option with the beta-3 adrenoreceptor agonists. This class demonstrates efficacy without anticholinergic adverse effects, enabling you to provide optimal, patient-centered care for residents of long-term care facilities. This PeerView educational activity is designed to help improve your ability to accurately recognize overactive bladder, apply appropriate diagnostic criteria, and incorporate newer treatment options. Expert faculty explain the clinically relevant ways in which the newer beta-3 adrenoreceptor agonists differ from traditional antimuscarinics, as well as how they differ from each other with regard to selectivity and safety. Upon completion of this activity, participants should be better able to: Recognize the individual, clinical, and economic burdens of OAB specific to patients living in long-term care facilities; Engage members of the healthcare team to routinely screen long-term care residents for symptoms of OAB; Apply recommended diagnostic criteria to differentiate OAB from other urinary conditions with shared symptomatology; and Implement individualized OAB treatment plans that minimize risks related to cardiovascular health, cognitive impairment and dementia, and polypharmacy concerns.

Barbara Burtness, MD - Building on the Immunotherapy Foundation for Head and Neck Cancer: Lessons Learned, Practical Guidance, and Next Steps in Care Jun 29, 2023

Show notes

Go online to PeerView.com/JQE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors have transformed the frontline management of recurrent/metastatic head and neck cancer (HNC)—but how can oncology professionals build on that foundation to expand the therapeutic applications of immunotherapy in HNC? This “MasterClass & Case Forum” activity, taken from a recent live event, features a panel of leading HNC experts sharing case-based insights on clinical decision-making with immunotherapy in recurrent/metastatic disease and beyond. Developed in collaboration with the Head and Neck Cancer Alliance (HNCA), each case-centric session also features the latest evidence on established and emerging immune-based treatments, combinational and sequential approaches, and the potential of checkpoint blockade in resectable and locally advanced disease. Upon completion of this activity, participants should be better able to: Cite the latest clinical evidence and guideline recommendations supporting the use of checkpoint inhibitors and other immunotherapy options for the management of HNC; Develop individualized treatment plans that incorporate checkpoint inhibitors and other immune modalities, including innovative combinational platforms, for the management of resectable, locally advanced, or recurrent/metastatic HNC; and Address practical aspects of care when using immunotherapy options, including provision of patient education and management of symptoms and immune-related AEs.

Elena Elimova, MD, M.Sc., FRcPC - Polishing Management Protocols in HER2-Expressing GI Cancers With Targeted Agents: A Focus on Refining Team-Based Strategies to Individualize BTC and GEA Care Jun 28, 2023

Show notes

Go online to PeerView.com/NXP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Emerging evidence supporting modern targeted strategies for the management of biliary tract cancers (BTC) and gastroesophageal adenocarcinoma (GEA) has led to the development of several agents to personalize therapy based on molecular findings. In this activity, our expert faculty will provide updates on evolving evidence-based practice standards and discuss how to effectively integrate the latest treatment advances into practice. You will learn to identify appropriate baseline diagnostic testing to inform the selection of targeted therapy for your patients with gastrointestinal cancers. Our experts will also introduce the latest evidence supporting relevant, novel strategies and explain when to initiate these agents in comparison with conventional treatment. Upon completion of this activity, participants should be better able to: Recognize current evidence supporting molecular testing, including HER2 expression, and its role in treatment selection for patients with HER2-positive GI cancers; Implement personalized treatment strategies based on molecular findings, current evidence and recommendations, and patient-specific factors when managing HER2-expressing GI cancers; and Apply practical strategies to manage and mitigate treatment-related AEs associated with HER2-targeting agents when managing BTC and GEA.

Jessica Ailani, MD, FAHS, FAAN, FANA - Breakthrough Therapies for the Prevention and Acute Treatment of Migraine: Addressing Unmet Needs in the Primary Care Setting Jun 27, 2023

Show notes

Go online to PeerView.com/MWU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, Dr. Jessica Ailani reviews the latest data on therapies for acute and preventive management of migraine, with a focus on personalized treatment. A patient interview and 3D animation are also part of this engaging video program. Upon completion of this activity, participants should be better able to: Apply safety and efficacy data related to new acute migraine therapies in clinical decision-making, taking into account patient-reported outcomes; Employ evidence-based prevention strategies for patients with migraine; and Implement individualized treatment plans for patients with migraine.

Luke Maese, DO, Rachel Rau, MD - Building a Foundation for Enhanced Outcomes in Pediatric ALL: Guidance on the Asparaginase Component of Modern Therapy Jun 27, 2023

Show notes

Go online to PeerView.com/TAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel antibodies, tyrosine kinase inhibitors, cellular therapy, and modern asparaginases, such as pegylated Escherichia coli and Erwinia chrysanthemi compounds have vastly improved treatment plans for pediatric and adolescent and young adult (AYA) populations with acute lymphoblastic leukemia (ALL). The approval of newer Erwinia formulations has expanded the therapeutic foundation on which clinicians can build effective strategies to address challenges such as asparaginase discontinuation due to hypersensitivity or silent inactivation. This "Clinical Consults" activity focuses on clinical decision-making related to the use of asparaginase compounds as part of pediatric and AYA ALL therapy. Watch experts provide guidance on the modern use of asparaginase therapy and share tactics for addressing real-world barriers to effective care, including hypersensitivity, silent inactivation, and asparaginase discontinuation, and get their perspectives on optimized asparaginase dosing and toxicity mitigation approaches. Learn how you can utilize modern asparaginase strategies to improve outcomes in ALL by watching today! Upon completion of this activity, participants should be better able to: Discuss current efficacy evidence and unmet needs related to the optimized use of asparaginase in pediatric ALL, including the role of novel Erwinia asparaginase compounds; Devise strategies to address therapeutically relevant considerations related to asparaginase use for pediatric ALL such as appropriate dosing, pre-empting truncation/discontinuation, and drug-related toxicity; Identify the emergence of asparaginase hypersensitivity, silent inactivation, or toxicity through the use of evidence-based monitoring plans in pediatric ALL; and Select treatment strategies to avoid asparaginase discontinuation and ensure adequate exposure to therapy, including switching to Erwinia asparaginase options after confirming hypersensitivity.

Jaime Almandoz, MD, MBA, FTOS - Practicing What We Preach: Your Role as an Obesity Medicine Specialist, Inspiring Change, and Overcoming Negative Weight Biases to Prioritize the Management of Obesity as a Chronic Disease Jun 20, 2023

Show notes

Go online to PeerView.com/QFA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this engaging activity, which is based on a pre-conference workshop held at OMA 2023, experts in obesity management aim to change misperceptions about obesity and explain best practices for treating this chronic condition, which include the importance of anti-obesity medications (AOMs) in achieving individualized weight goals and improving overall health outcomes by reducing the risk and progression of obesity-related comorbidities. Upon completion of this activity, participants should be better able to: Initiate appropriate, unbiased, and nonjudgmental conversations with patients about obesity acknowledging it as a chronic, treatable disease rather than a result of personal irresponsibility; Compare the efficacy and safety profiles of current and emerging anti-obesity medications and their potential to support weight loss efforts and minimize the impact of obesity-related comorbidities; and Employ shared decision-making to implement a comprehensive, individualized treatment plan that incorporates appropriate use of long-term anti-obesity medications to achieve and maintain realistic weight loss in people with obesity.

Brett Elicker, MD - Taking a Look Ahead in Non–Cystic Fibrosis Bronchiectasis: Leveraging Early Diagnosis and Emerging Therapies to Improve Quality of Life Jun 20, 2023

Show notes

Go online to PeerView.com/SND860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Non–cystic fibrosis bronchiectasis (NCFBE) is a long-term respiratory condition with a significant impact on quality of life, morbidity, mortality, and use of healthcare resources. Recurrent infections, persistent cough, sputum production, and exacerbations can lead to disease worsening, making early diagnosis of paramount importance. Healthcare professionals involved in the diagnosis of patients with bronchiectasis must be aware of the various etiologies and CT features associated with NCFBE. This question-based educational activity will review these topics and make it easy to claim your CME/MOC credit. Upon completion of this activity, participants should be better able to: Use risk factors, signs and symptoms, testing, and imaging to facilitate accurate and prompt diagnosis and intervention to minimize progression of NCFBE; Describe underlying pathophysiologic mechanisms, including the role of neutrophilic inflammation and neutrophil serine proteases in NCFBE and their correlation to emerging therapies; and Incorporate existing and emerging therapies into customized management plans to decrease exacerbations and increase quality of life.

Kimberly Halla, MSN, FNP-C - Expert Nursing Insights on Personalized Care for Gynecologic Cancers: Educating and Supporting Patients on the Latest Therapeutic Approaches Jun 08, 2023

Show notes

Go online to PeerView.com/VRD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the therapeutic landscape for gynecologic cancers (ovarian, endometrial, and cervical) rapidly evolves, how can oncology nurses effectively support patients and integrate the growing clinical evidence for approved and emerging strategies? Nurses can rise to the challenge with this PeerView Live MasterClass & Nursing Practice Forum, based on a recent live event developed in collaboration with the National Ovarian Cancer Coalition. An expert panel showcases what nursing professionals should know about diagnostic testing, PARP inhibitors, immunotherapy options, and managing potential adverse events. Through the lens of patient case scenarios, they will also share personal reflections on supporting patients throughout their treatment process. Upon completion of this activity, participants should be better able to: Review current efficacy and safety evidence of immunotherapy and PARP inhibitors in gynecologic malignancies such as endometrial, cervical, and ovarian cancers; Implement nurse-guided strategies to integrate approved and emerging systemic therapy options into personalized management and education plans for patients with gynecologic cancers, including information on diagnostic testing, therapeutic expectations, safety considerations, and clinical trial opportunities; and Apply effective team-based safety strategies to promptly identify, mitigate, manage, and counsel patients on the spectrum of adverse events associated with systemic therapy for endometrial, cervical, and ovarian cancers.

Laura Klesse, MD, PhD / Carlos G. Romo, MD - The Bedrock of Personalized NF1 Care: Fundamentals of Managing NF1-Associated PNs and Other Tumors With Innovative Targeted Therapy Jun 06, 2023

Show notes

Go online to PeerView.com/RFJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recent developments targeting the RAS/MAPK signaling pathway have led to the first approved MEK inhibitor for the treatment of pediatric patients with symptomatic, inoperable PNs. To help lay the foundation of personalized NF1 care, this activity—based on a live event at the recent ASPHO meeting—features expert panelists sharing real-world cases to illustrate the collaborative management of NF1 tumors with highly efficacious targeted agents. The case-based conversations cover the diagnostic-treatment arc of NF1-PNs, culminating with tips and tactics arising from the clinical experience with MEK inhibitors—and going beyond to include insights on targeted strategies in other NF1 tumor settings. Watch now to start building your personalized management on a bedrock of solid science! Upon completion of this activity, participants should be better able to: Summarize current evidence and guideline recommendations supporting modern diagnostic strategies and treatment plans incorporating targeted agents, including MEK inhibitors, for the management of pediatric patients with NF1-related PNs and other tumors; Develop evidence-based treatment plans using MEK inhibitors and other targeted therapies for the management of pediatric patients with NF1-related PNs and other tumors based on prognostic information and safety considerations; and Manage practical aspects of patient care when using innovative targeted approaches, including patient/caregiver education, monitoring, and the unique spectrum of adverse events.